Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis

NCT03055195 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
34
Enrollment
INDUSTRY
Sponsor class

Stopped Study reached pre-determined futility criteria following interim analysis. No safety concerns were noted.

Conditions

Interventions

Sponsor

GlaxoSmithKline